A trial of antithrombotic therapy in patients with refractory migraine and antiphospholipid antibodies: A retrospective study of 75 patients
- 5 January 2021
- journal article
- research article
- Published by SAGE Publications in Lupus
- Vol. 30 (4) , 568-577
Abstract
Objective: It has been reported that patients with antiphospholipid antibodies (aPL) and refractory migraine may experience symptomatic improvement with antithrombotic therapy, but this phenomenon has not been well studied. This study was undertaken to detail the response to trials of antithrombotic therapy in these patients. Methods: This is a retrospective study of 75 patients with refractory migraine and aPL who were given a 2–4 week trial of aspirin, clopidogrel and/or anticoagulation. Major response was defined as 50–100% improvement in frequency and/or severity of migraine; minor response: 25–49% improvement; no response: <25% improvement. Results: 66 patients were given a trial of aspirin: 47% responded (21% major); 60 patients were given a trial of clopidogrel: 83% responded (67% major); and 34 patients were given a trial of anticoagulation (usually apixaban): 94% responded (85% major). The response rate to any anti-thrombotic therapy was 89% (83% major). Many patients also noted improvement in non-headache symptoms. No patient experienced stroke. There was no major bleeding during any 2–4 week treatment trial and only 3 of 69 patients maintained on an antithrombotic regimen for a median follow up of 29.9 months (5–100) experienced major bleeding. Conclusions: There was a high rate of symptomatic response to antithrombotic therapy in this context and long-term follow up suggested an individualized symptom-derived antithrombotic regimen may be associated with a low bleeding risk. Our data support consideration of a 2–4 week trial of antithrombotic therapy, usually starting with antiplatelet therapy, in aPL-positive patients with refractory migraine, particularly if other treatment options have been exhausted. As a retrospective study, our data provide only Class IV level of evidence, but they suggest randomized controlled trials are warranted to validate these encouraging findings.Keywords
This publication has 25 references indexed in Scilit:
- Increased Risk of Hemorrhagic Stroke in Patients with Migraine: A Population-Based Cohort StudyPLOS ONE, 2013
- Complex Migraine with Subtherapeutic INR in Antiphospholipid SyndromeThe American Journal of Medicine, 2012
- Heparin, antiphospholipid antibodies and the brainLupus, 2012
- Migraineurs show a high prevalence of antiphospholipid antibodiesJournal of Thrombosis and Haemostasis, 2011
- Antiphospholipid syndrome, migraine and strokeLupus, 2010
- Neurological Dysfunction Associated with Antiphospholipid Syndrome: Histopathological Brain Findings of Thrombotic Changes in a Mouse ModelJournal of Immunology Research, 2004
- Headache and memory loss: rapid response to heparin inthe antiphospholipid syndromeLupus, 2001
- Sticky blood and headacheLupus, 2001
- The Management of Thrombosis in the Antiphospholipid-Antibody SyndromeNew England Journal of Medicine, 1995
- ANTIPHOSPHOLIPID ANTIBODY SYNDROME PRESENTING WITH COMPLEX PARTIAL SEIZURES AND TRANSIENT ISCHAEMIC ATTACKS DUE TO WIDESPREAD SMALL CEREBRAL ARTERIAL THROMBOSISNeuropathology and Applied Neurobiology, 1989